



## Company announcement

17 November 2017

### NeuroSearch upgrades its guidance for 2017

NeuroSearch upgrades its guidance for 2017 from an operating loss of DKK 2.3-3.3 million, to an operation loss of approximately DKK 1 million. The outlook does not include any income from the possible divestment of additional Company assets or potential income from the Company's agreement with Teva.

### Contact

Allan Andersen, CEO, mobile +45 4016 3864.

### About NeuroSearch

NeuroSearch A/S (NEUR) is listed on Nasdaq Copenhagen A/S.